Clinical-stage biopharma company Mersana Therapeutics unveiled a global collaboration with GlaxoSmithKline Monday that gives the industry behemoth the exclusive option to co-develop and commercialize Mersana’s antibody-drug conjugate (ADC) XMT-2056.
Posts
MiroBio and Gilead believe they can offer new, best-in-class assets to patients beset by different autoimmune diseases. The deal includes MiroBio’s lead investigational candidate, MB272, a selective agonist of T, B and dendritic cells that aims to inhibit or blunt activation and suppress an inflammatory immune response.
Marengo Therapeutics and Ipsen announced Monday that they have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.